TUSTIN, Calif., Nov. 29 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (Jade), is an international biopharma company and today announced that Jade has received the Brand Excellence Award from the Chinese Federation of Industry and Commerce for its state-of-the-art anti-aging treatment Goodnak(R).
The Chinese Federation hailed Goodnak(R) as a breakthrough Chinese medical/beauty product at a gala ceremony in Shenzhen, China, where the award was presented to Jade executives, who said it is set to become one of the premiere beauty products in China.
Goodnak(R) is a high quality injectable anti-aging & skin care product that contains an amalgam of various therapeutic elements including human placental histosolution (HPH). Jade has begun selling Goodnak(R) through wholesale distribution channels that service high-end beauty salon and plastic surgery hospitals and medical cosmetology institutions. Goodnak product information is available on Jade Pharma's product specific website: http://www.jade-amdl.com.
Gary Dreher, CEO of AMDL, noted that AMDL is now a health care company, with noteworthy pharmaceutical products for treating disease, a diagnostic company, with a test to detect cancer at early stages, and a nutraceutical Company, with significant products for wellness. "We are confident that Goodnak(R) will become a large part of our success both short and longterm," Mr. Dreher said.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its Jade subsidiaries, currently holds licenses for 133 products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
Forward-Looking Statements: This news release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements are subject to certain risks and
uncertainties, and actual circumstances, events or results may differ
materially from those projected in such forward-looking statements. The
Company cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically disclaims any
obligation, to update or revise such statements to reflect new
circumstances or unanticipated events as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
Voice Mail: 714.505.4460
|SOURCE AMDL, Inc.|
Copyright©2007 PR Newswire.
All rights reserved